Table 3 Results of the ipratropium study (study 2)
Bronchodilator | Ipratropium | Salbutamol | ||
|---|---|---|---|---|
Treatment | Placebo | Formoterol | Placebo | Formoterol |
Pre-challenge FEV1 (L) (SD) | 2.77 (0.50) | 2.67 (0.41) | 2.62 (0.50) | 2.67 (0.63) |
Post-challenge FEV1(L)(SD) | 2.15 (0.38) | 2.07 (0.37) | 2.06 (0.41) | 2.11 (0.60) |
PD20 saline (ml) (95% CI) | 11.8 (7.4–19) | 8.0 (4.6–13.8) | 8.9 (4.9–16.0) | 8.6 (5.0–14.6) |
AUC %.time (SD) | 447 (215) | 401 (154) | 759 (203) | 557 (131) |
Difference: paired t-test (95% CI) | 138 (-48,138) p = 0.303 | 202 (66, 339) p = 0.008 | ||
Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI) | 88 (-31, 207) p = 0.126 | 202 (42, 362) p = 0.019 | ||
FEV1 at 30 mins (L) (SD) | 2.81 (0.54) | 2.67 (0.45) | 2.91 (0.56) | 2.74 (0.64) |
Difference: paired t-test (95% CI) | 0.22 (0–0.30) p = 0.056 | 0.10 (-0.05, 0.39) p = 0.117 | ||
Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI) | 0.11 (-0.06, 0.28) p = 0.172 | 0.22 (0.05, 0.38) p = 0.015 | ||